EP300 sirna

EP300 siRNA (Human)

Cat. Num. AAA8208327

• Gene Names: EP300; p300; KAT3B; RSTS2
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: EP300; EP300 siRNA (Human); P300; Histone acetyltransferase p300; p300 HAT; E1A-associated protein p300; EP300 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: EP300 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 2414

• Applicable Applications for EP300 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human EP300 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for EP300 sirna

siRNA to inhibit EP300 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 50345997
• NCBI GeneID: 2033
• NCBI Accession #: NP_001420.2
• NCBI GenBank Nucleotide #: NM_001429.3
• UniProt Accession #: Q09472; B1AKC2
• Molecular Weight: 264,161 Da
• NCBI Official Full Name: histone acetyltransferase p300
• NCBI Official Synonym Full Names: E1A binding protein p300
• NCBI Official Symbol: EP300
• NCBI Official Synonym Symbols: p300; KAT3B; RSTS2
• NCBI Protein Information: histone acetyltransferase p300
• UniProt Protein Name: Histone acetyltransferase p300
• Protein Family: EP300-interacting inhibitor of differentiation
• UniProt Gene Name: EP300
• UniProt Synonym Gene Names: P300; p300 HAT
• UniProt Entry Name: EP300_HUMAN

NCBI Description

This gene encodes the adenovirus E1A-associated cellular p300 transcriptional co-activator protein. It functions as histone acetyltransferase that regulates transcription via chromatin remodeling and is important in the processes of cell proliferation and differentiation. It mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. This gene has also been identified as a co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Defects in this gene are a cause of Rubinstein-Taybi syndrome and may also play a role in epithelial cancer. [provided by RefSeq, Jul 2008]

Uniprot Description

p300: a histone acetyltransferase and transcriptional co-activator that regulates transcription via chromatin remodeling. Acetylates all four core histones in nucleosomes. Related to CPB (CREB-binding protein), and like CPB can stimulate transcription through activation of CREB. Specifically inhibited by the adenovirus oncoprotein E1A. A co-activator of HIF1A (hypoxia-inducible factor 1 alpha), and thus plays a role in the stimulation of hypoxia-induced genes such as VEGF. Mediates cAMP-gene regulation by binding specifically to phosphorylated CREB protein. Methylated at R580 and R604 in the KIX domain by CARM1, which blocks association with CREB, inhibits CREB signaling and activates the apoptotic response. Also methylated at R2142 by CARM1, which impairs interaction with NCoA2.

Protein type: EC 2.3.1.48; Acetyltransferase; Nuclear receptor co-regulator; Motility/polarity/chemotaxis; Transcription, coactivator/corepressor

Chromosomal Location of Human Ortholog: 22q13.2

Cellular Component: nucleoplasm; transcription factor complex; cytoplasm; nucleus; histone acetyltransferase complex

Molecular Function: lysine N-acetyltransferase activity; transcription activator binding; zinc ion binding; p53 binding; chromatin DNA binding; transcription coactivator activity; beta-catenin binding; transcription factor binding; protein binding; histone acetyltransferase activity; androgen receptor binding; DNA binding; acetyltransferase activity; transferase activity, transferring acyl groups; chromatin binding; nuclear hormone receptor binding

Biological Process: circadian rhythm; establishment and/or maintenance of chromatin architecture; viral reproduction; positive regulation of protein binding; regulation of cell cycle; apoptosis; heart development; positive regulation of transcription of target genes involved in unfolded protein response; negative regulation of transcription from RNA polymerase II promoter; regulation of transcription, DNA-dependent; positive regulation of interferon type I production; G2/M transition of mitotic cell cycle; DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis; nervous system development; somitogenesis; Notch signaling pathway; skeletal muscle development; internal peptidyl-lysine acetylation; transcription, DNA-dependent; protein stabilization; organ morphogenesis; protein amino acid acetylation; response to estrogen stimulus; response to hypoxia; innate immune response; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription factor activity; mitotic cell cycle; internal protein amino acid acetylation; lung development; N-terminal peptidyl-lysine acetylation

Disease: Rubinstein-taybi Syndrome 2; Rubinstein-taybi Syndrome 1; Colorectal Cancer